EXHIBIT 10.2
THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAW. SUCH
SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR UNLESS SUCH SALE OR TRANSFER IS EXEMPT FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT OR THE
ISSUER HAS RECEIVED AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
REASONABLY ACCEPTABLE TO THE ISSUER THAT REGISTRATION IS NOT
REQUIRED UNDER THE ACT OR APPLICABLE STATE SECURITIES
LAWS .
THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
DOR BIOPHARMA,
INC.
Warrant for the Purchase of
Shares of
Common
Stock
No.
Original
Issue Date September __, 2009
FOR VALUE RECEIVED, DOR BIOPHARMA,
INC., a Delaware corporation (the " Company "), hereby
certifies that ___________________(the “ Holder
”), is entitled to purchase from the Company, at any time or
from time to time commencing after the Original Issue Date and
expiring at 5:00 P.M., New York City time, on the fifth (5th)
anniversary after the Original Issue Date (as such date may be
changed pursuant to Section 2 hereof, the “ Expiration
Date ” being September __, 2014,
______________________ (________), fully paid and
non-assessable shares of Common Stock, par value $.001 per share,
of the Company (the “ Warrant Shares ”) for a
per share exercise price equal to $0.278 per share (the
“ Per Share Warrant Price ”). The Per Share
Warrant Price is subject to adjustment as hereinafter provided.
Capitalized terms used and not otherwise defined in this Warrant
shall have the meanings specified in Section 9, unless the context
otherwise requires.
(a) This
Warrant may be exercised, in whole at any time or in part from time
to time, commencing after the Original Issue Date and expiring at
5:00 P.M., New York City time, on the Expiration Date (with the
Exercise Notice at the end of this Warrant duly executed) at the
address set forth in Section 10 hereof, together with payment of
the Per Share Warrant Price multiplied by the number of Warrant
Shares to which such exercise relates made by delivery to the
Company of one or more types of Permitted Consideration.
(b) If
this Warrant is exercised in part, the Company will deliver to the
Holder within ten Trading Days of the date such Holder delivers to
the Company this Warrant and an Exercise Notice, together with the
payment of the aggregate Per Share Warrant Price for such exercise,
a new Warrant covering the Warrant Shares which have not been
exercised. By the expiration of the third Trading Day
following the Holder’s delivery of a Warrant, together with
an Exercise Notice and the payment of the aggregate Per Share
Warrant Price for such exercise, the Company will (i) issue a
certificate or certificates in the name of the Holder for the
largest number of whole shares of the Common Stock to which the
Holder shall be entitled and, if this Warrant is exercised in
whole, in lieu of any fractional share of the Common Stock to which
the Holder shall be entitled, pay to the Holder cash in an amount
equal to the fair value of such fractional share (determined by
reference to the closing sales price of the Common Stock on the
date of the Exercise Notice), and (ii) deliver the other securities
and properties receivable upon the exercise of this Warrant, or the
proportionate part thereof if this Warrant is exercised in part,
pursuant to the provisions of this Warrant.
(c) If, six months after the
Original Issue Date, the Warrant Shares to be issued are not
registered and available for resale by the Holder pursuant to a
registration statement in accordance with the Registration Rights
Agreement entered into on the date hereof, then the Holder may, at
its election exercised in its sole discretion, exercise this
Warrant in whole or in part and, in lieu of making a cash payment
of Permitted Consideration, elect instead to receive upon such
exercise the “Net Number” of shares of Common Stock
determined according to the following formula:
Net Number = (A x B) – (A x
C)
For purposes of the foregoing
formula:
A=the total number of Warrant Shares
with respect
to which this Warrant is then being
exercised.
B=the average of the closing sales
prices for the five
Trading Days immediately prior to
(but not including)
the day that the Holder delivers the
Exercise Notice at issue.
C=the Per Share Warrant
Price;
provided, however that Holder may
not exercise this Warrant in whole or in part pursuant to this
Section 1(c) if a registration statement has been filed but the
Holder is not permitted to use the prospectus included in such
registration statement.
(d) If, by the third Trading Day
after the date that the Holder delivers an Exercise Notice,
together with the payment of the aggregate Per Share Warrant Price
for such exercise, the Company fails to deliver the required number
of Warrant Shares in the manner required pursuant to Section 1(b),
then the Holder will have the right to rescind such
exercise.
(e) If,
by the third Trading Day after the date that the Holder delivers an
Exercise Notice, together with the payment of the aggregate Per
Share Warrant Price for such exercise, the Company fails to deliver
the required number of Warrant Shares in the manner required
pursuant to Section 1(b), and if after such third Trading Day and
prior to the receipt of such Warrant Shares, the Holder purchases
(in an open market transaction or otherwise) shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a
" Buy-In "), then the Company shall (1) pay in cash to the
Holder the amount by which (x) the Holder's total purchase price
(including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying
(A) the number of Warrant Shares that the Company was required to
deliver to the Holder in connection with the exercise at issue by
(B) the closing bid price of the Common Stock at the time of the
obligation giving rise to such purchase obligation and (2) at the
option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was
not honored or deliver to the Holder the number of shares of Common
Stock that would have been issued had the Company timely complied
with its exercise and delivery obligations
hereunder. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of
the Buy-In.
(f) Notwithstanding anything to the
contrary contained herein, the number of shares of Common Stock
that may be acquired by the Holder upon any exercise of this
Warrant shall be limited to the extent necessary to insure that,
following such exercise, the total number of shares of Common Stock
then beneficially owned by such Holder and its affiliates and any
other persons whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of Section 13(d) of
the Exchange Act, does not exceed 4.999% of the total number of
issued and outstanding shares of Common Stock (including for such
purpose the shares of Common Stock issuable upon such exercise).
For such purposes, beneficial ownership shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. Each delivery of an Exercise
Notice will constitute a representation by the Holder that it has
evaluated the limitation set forth in this paragraph and determined
that issuance of the full number of Warrant Shares requested in
such Exercise Notice is permitted under this paragraph. This
provision shall not restrict the number of shares of Common Stock
which a Holder may receive or beneficially own in order to
determine the amount of securities or other consideration that such
Holder may receive in the event of a Fundamental Transaction as
contemplated in Section 3. By written notice to the Company, the
Holder may waive the provisions of this Section but any such waiver
will not be effective until the 61st day after such notice is
delivered to the Company.
2.
Company’s Option to Change Expiration Date
.
Notwithstanding anything herein to
the contrary, in the event that (i) the closing sales price per
share of Common Stock is in excess of 300% of the Per Share Warrant
Price (as may be adjusted pursuant to Section 3) for any twenty
(20) Trading Days during any thirty (30) consecutive Trading Days,
(ii) the Warrant Shares are either registered for resale pursuant
to an effective registration statement naming the Holder as a
selling stockholder thereunder (and the prospectus thereunder is
available for use by the Holder as to all then available Warrant
Shares) or freely transferable without volume restrictions pursuant
to Rule 144(k) promulgated under the Securities Act, as determined
by counsel to the Company pursuant to a written opinion letter
addressed and in form and substance reasonably acceptable to the
Holder and the transfer agent for the Common Stock, during the
entire twenty (20) Trading Day period referenced in (i) above
through the expiration of the Call Date as set forth in the
Company’s notice pursuant to this Section (the “Call
Condition Period” ), and (iii) the Company shall have
complied in all material respects with its obligations under this
Warrant and under the Purchase Agreement, then, subject
to the conditions set forth in this
Section, the Company may, in its sole discretion, elect to change
the Expiration Date to 5:00 P.M., New York City time on the
Holder’s warrants on the date that is thirty (30) days after
written notice thereof (a “Call Notice” ) is
received by the Holder (the “Call Date” ) at the
address last shown on the records of the Company for the Holder or
given by the Holder to the Company for the purpose of notice;
provided, that the conditions to giving such notice must be in
effect at all times during the Call Condition Period or any such
notice shall be null and void. The Company and
the Holder agree that, if and to the extent Section 1(f)
or (g) of this Warrant would restrict the ability of the Holder to
exercise this Warrant in the event of a delivery of a Call Notice,
then notwithstanding anything to the contrary set forth in the
Call Notice, the Call Notice shall be deemed automatically
amended to apply only to such portion of this Warrant as may
be exercised by the Holder by the Call Date in accordance with
Section 1(f) and (g). The Holder will promptly (and, in any
event, prior to the Call Date) notify the Company in writing
following receipt of a Call Notice if Section 1(f) or (g)
would restrict its exercise of the Warrant, specifying therein the
number of Warrant Shares so restricted.
3.
Certain Adjustments . The Per Share Warrant Price
and number of Warrant Shares issuable upon exercise of this Warrant
are subject to adjustment from time to time as set forth in this
Section 3.
(a) If the Company, at
any time while this Warrant is outstanding, (i) pays a stock
dividend on its Common Stock or otherwise makes a distribution on
any class of capital stock that is payable in shares of Common
Stock, (ii) subdivides outstanding shares of Common Stock into a
larger number of shares, or (iii) combines outstanding shares of
Common Stock into a smaller number of shares, then in each such
case the Per Share Warrant Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common
Stock outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment
made pursuant to clause (i) of this paragraph shall become
effective immediately after the record date for the determination
of shareholders entitled to receive such dividend or distribution,
and any adjustment pursuant to clause (ii) or (iii) of this
paragraph shall become effective immediately after the effective
date of such subdivision or combination.
(b) If, at any time while this
Warrant is outstanding, (1) the Company effects any merger or
consolidation of the